Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that localized skin calcification could be induced in adult rats through dihydrotachysterol treatment combined with topical trauma, offering an experimental model for calcifying scleroderma.

In this study, a systematic review found that for androgenetic alopecia, systemic treatments like finasteride, dutasteride, and oral minoxidil are effective at slowing progression and promoting hair regrowth, with additional antiandrogen therapy options for women.

Different treatments for skin conditions were found to be effective and generally safe, with biologics recommended as the first choice for generalized pustular psoriasis.

This review reports that while finasteride effectively treats androgenetic alopecia and benign prostatic hyperplasia, persistent adverse effects on sexual, psychological, and metabolic health have been noted, highlighting the need for ongoing research and careful risk assessment for safer clinical usage.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This review found that dutasteride is more effective than finasteride in increasing hair count and shaft thickness for androgenetic alopecia in men, with potential for reduced systemic side effects through mesotherapy, although further research is needed on long-term safety and dosage.

This study found that while systemic absorption of DHT from liposomes was negligible, the topical biological effect was weaker compared to DHT dissolved in acetone on the female hamster flank organ model.

This review discusses the mechanisms and treatment strategies for age-related hair changes, such as androgenetic alopecia and hair graying, and reports no new clinical results.

Recent hair loss research shows some progress, especially in understanding male pattern baldness, but effective treatments for many types of hair loss are still lacking.

This article reviews the use of anti-androgens for dermatological conditions linked to androgen involvement and reports encouraging clinical experiences in females, with use in males limited to specific conditions due to toxicity concerns.

In a mouse model study, researchers developed a methacrylated hyaluronic acid-based hydrogel microneedle patch co-loaded with finasteride and a carbon monoxide-releasing molecule for androgenetic alopecia, which showed better hair regrowth and safety compared to traditional treatments, offering an innovative approach with minimized systemic side effects.

This literature review found that androgenetic alopecia has a complex multifactorial etiology and effective management should be tailored to individual severity and gender to improve patients' quality of life.

In this review, researchers explored the potential of topical finasteride as an innovative treatment for male pattern hair loss, addressing the limitations of oral finasteride, such as side effects and inconsistent effectiveness.

This study reviewed early research on topical finasteride for androgenetic alopecia, finding it appears safe and promising, though further investigation is needed to determine optimal dosing, frequency, and potential applications for other types of alopecia.

AGA causes permanent hair loss; minoxidil helps men, finasteride helps men, minoxidil somewhat helps women, estrogens/antiandrogens lack evidence for women.

This source reports that clascoterone cream, a topical androgen receptor inhibitor, has shown effectiveness in treating facial acne vulgaris in patients 12 and older, with clinical trials indicating a favorable safety profile compared to systemic treatments, and potential for broader dermatological applications.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.

In this narrative review, researchers reported that oral finasteride significantly improved hair count and density in male androgenetic alopecia but had higher systemic exposure and potential side effects compared to topical formulations, which provided similar efficacy with lower systemic DHT suppression.

This chapter reviews ethosomes for targeted drug delivery to the scalp in androgenetic alopecia and reports no clinical results; the authors emphasize reducing systemic side effects.

This study found that in an androgenetic alopecia mouse model, phospholipid-bile salt mixed micelles for topical Finasteride delivery improved hair regrowth and reduced systemic absorption compared to a hydroalcoholic solution, suggesting a safer and more effective treatment option.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.

This review examines natural bioactive compounds for their potential to alleviate androgenetic alopecia, emphasizing compounds like ginseng and curcumin, but reports no new experimental results.

This study describes a case where finasteride treatment for benign prostatic hypertrophy was associated with gynecomastia in a 62-year-old man, which resolved after the drug was discontinued.

This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.

This review discusses potential causes of androgenic alopecia and explores treatment options, but provides no new clinical results; it emphasizes considering androgen overproduction syndromes in female patients.

This study observed that a topical liposome formulation of a 5‐α‐reductase inhibitor effectively reduced the size of treated sebaceous glands and induced apoptosis in a hamster model, suggesting potential benefits for acne treatment.

This study found that male pattern baldness may serve as a clinical marker for circulating sex hormone levels in men with localized prostate cancer, while chest hair density showed no significant hormone association.

Scale created to measure hair loss in men and women; MK-386 reduces acne; Niaspan treats dyslipidemia; minoxidil increases heart rate.

In this case report, the authors describe a partial androgen insensitivity syndrome patient with a novel AR gene mutation, highlighting challenges in gender assignment decisions for infants with partial AIS.